Characterizations of the 2013 Lublin MS Phenotypes in a Single-Center Dataset (P1.112)

OBJECTIVE: We aimed to describe the Lublin phenotypes in a single center dataset. BACKGROUND: A Revision defining the clinical phenotypes of MS was recently described by Lublin et al. (2014). DESIGN/METHODS: We retrospectively examined the newly described phenotypes of MS in 176 longitudinally studied patients. Based on the Lublin schema, we categorized patients on a yearly basis into one of six clinical phenotypes, beginning with the first year of MS, after diagnosis. Phenotype 1 was stable relapsing remitting MS (RRMS); type 2 was active RRMS; type 3 was active secondary progressive MS (SPMS) with progression; type 4 was active SPMS without progression; type 5 was non-active SPMS but with progression; and type 6 was non-active SPMS and without progression. RESULTS: Of the 176 patients, 149 (84.7[percnt]) transitioned to some type of SPMS during their disease duration, while 27/176 (15.3[percnt]) patients continued to have RRMS during the 12.62±4.18 year follow up. None of the patients with RRMS had a final EDSS of equal to or greater than 6.0 at last examination, whereas 27/149 (18.1[percnt]) of the patients transitioning to SPMS remained at an EDSS of equal to or greater than 6.0, p=0.02. We found phenotype 3 to be rare, as only 10/176 (5.7[percnt]) patients progressed via this phenotype within one or more of the first ten years of disease. Patients progressing by type 3 had a higher EDSS score after ten years of disease duration (p<0.001) and a higher MS Severity Score (MSSS) at last examination (p<0.001). CONCLUSION: We were able to characterize MS patients based on clinical phenotypes described by Lublin et al. (2014). Disclosure: Dr. Gettings has nothing to disclose. Dr. Hackett has nothing to disclose. Dr. Schramke has nothing to disclose. Dr. Scott has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, Genzyme Corporation, Novartis, and Teva Neuroscience as a consultant and/or speaker.